Astec Lifesciences Ltd

Astec Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 September 2024. However, the analysis and financial metrics presented here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Astec Lifesciences Ltd, a key player in the Pesticides & Agrochemicals sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock’s technical indicators reveal a mixed picture that investors should carefully analyse amid ongoing market volatility.

Astec Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest intraday price gain of 1.01%, the broader technical landscape suggests caution for investors as bearish signals intensify across multiple timeframes.

Astec Lifesciences Ltd, a key player in the Pesticides & Agrochemicals sector, has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a modest day gain of 0.50% to close at ₹627.10, the stock’s technical parameters reveal a transition from a bearish to a mildly bearish trend, underscoring cautious optimism amid persistent headwinds.

Astec Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 September 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 25 February 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical standing.

Astec Lifesciences Ltd, a key player in the Pesticides & Agrochemicals sector, is currently exhibiting a pronounced shift towards bearish momentum as multiple technical indicators signal a deteriorating trend. With a recent downgrade to a Strong Sell rating and a Mojo Score of 17.0, the stock’s technical landscape suggests caution for investors amid weakening price action and subdued market sentiment.

Astec Lifesciences Ltd, a player in the Pesticides & Agrochemicals sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock’s price action and technical parameters warrant a detailed analysis for investors navigating this challenging environment.

Astec Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 September 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 13 February 2026, providing investors with the latest insights into its performance and outlook.

Astec Lifesciences Ltd recorded a robust intraday performance on 5 Feb 2026, surging to a day’s high of Rs 676.25, marking an 11.25% increase from its previous close. The stock outperformed its sector and broader market indices, reflecting heightened trading activity and volatility throughout the session.

Astec Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 September 2024. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 02 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Astec Lifesciences Ltd, a player in the Pesticides & Agrochemicals sector, has touched a new 52-week low of Rs.555.4 today, marking a significant decline in its stock price amid a broader sectoral downturn and persistent underperformance over the past year.

Astec LifeSciences Ltd., a prominent manufacturer of agrochemical active ingredients and pharmaceutical intermediates, reported a consolidated net loss of ₹15.70 crores for Q3 FY26, representing a 61.12% deterioration compared to the ₹40.38-crore loss recorded in Q3 FY25. Despite a robust 32.88% year-on-year revenue expansion to ₹124.72 crores, the company continues to grapple with operational inefficiencies and mounting interest burdens that have kept profitability elusive. The stock, currently trading at ₹573.00 with a market capitalisation of ₹1,289 crores, has plunged 42.46% over the past year, significantly underperforming both the Sensex and its sectoral peers.

Astec Lifesciences Ltd, a player in the Pesticides & Agrochemicals sector, has touched a new 52-week low of Rs.559.3 today, marking a significant decline in its stock price amid persistent downward momentum and underperformance relative to its sector and benchmark indices.

Astec Lifesciences Ltd, a key player in the Pesticides & Agrochemicals sector, recorded a new 52-week low of Rs.575.45 today, marking a significant decline in its stock price amid broader market pressures and company-specific financial strains.

Astec Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 September 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here represent the company’s current position as of 22 January 2026, providing investors with an up-to-date perspective on its performance and prospects.